3-(4-Bromophenyl)-1-(2-cyanoethyl)-1H-pyrazole-4-carbonitrile, 95.0%, 500mg

1-(BENZENESULFONYL)-6-IODO-2-METHYL-1H-INDOLE, 95.0%, 5g

Oxion Inverso OX.2053-PLPH with LWD Plan phase 10x/20x/40x objectives and XY cross table

1-(2-Chlorophenyl)imidazole, 99.0%, 250mg

Acetyl Bromide>97.0%(T)500g

5-(Hydroxymethyl)pyrrolidin-2-one, 95.0%, 25g

3-Bromo-5-methoxy-4-methylpyridine, 95.0%, 25g

N-[(1S,2S)-2-(Dimethylamino)cyclohexyl]-N'-[(1S,2R)-2-hydroxy-1,2-diphenylethyl]thiourea, 97%, 100mg

tert-Butyl 4-(3-bromo-1H-pyrazol-1-yl)piperidine-1-carboxylate, 95.0%, 10g

Methyl (S)-2-amino-3-(4-(difluoromethoxy)phenyl)propanoate hydrochloride, 98+%, 250mg

1-(2-Methylphenoxy)-2-propanol>90.0%(GC)5g

8-[(E)-2-(3,4-Dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6 -dione, 95.0%, 100mg

3-(3-(Bromomethyl)phenyl)-5-methyl-1,2,4-oxadiazole, 95.0%, 250mg